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INTRODUCTION 
Pain is universally understood as a signal of disease, and 
is one of the most common symptoms that gets patients’, 
and in turn physicians’ attention. Patients of chronic pain 
are treated with various medications such as non-
steroidal anti-inflammatory drugs (NSAIDs), opioids, 
anticonvulsants, antidepressants like tricyclic 
antidepressants and selective serotonin reuptake 
inhibitors (SSRIs), but none of them have shown 
outstanding efficacy for relieving chronic pain. The 
NSAIDs are non-specific analgesics; opioids although 
the most efficacious have dose-limiting side-effects like 
sedation, respiratory depression, pruritus, constipation 
and dependence liability. 
1, 2
 
Numerous open and controlled studies have shown that 
antidepressant drugs also have analgesic activity and 
particularly, SSRIs are effective in mixed and chronic 
pain. 
3
 On the other hand there are some studies that 
have altogether denied the analgesic role of SSRI. 
4,5,6
 
Another challenging aspect is the meager understanding 
regarding their mechanism of action. The underlying 
mechanism for the antinociceptive action of these agents 
probably involves a complex interaction between several 
neurotransmitter systems and neuroreceptors. 
7
 There is 
ample evidence to suggest that pain inhibitory pathway 
involves monoamines such as noradrenalin (NA) and 5-
hydroxy triptamine (5-HT) and SSRI by increasing the 
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serotonin level may inhibit the release of 
neurotransmitter carrying the pain sensation from nerve 
endings. 
8,9
 A direct activation of the endogenous opioid 
system or potentiation of a mixed analgesic effect 
mediated by serotonergic and/or noradrenergic pathways 
or combinations of these mechanisms are thought to be 
involved in the antinociceptive action mechanisms of 
SSRIs. 
10
 
Despite such an enormity of literature, it is not yet clear 
whether these can be used as analgesics and if so, what 
could be the underlying mechanism. Therefore, the 
present study was planned with the aim of confirming 
the antinociceptive activity of one of the antidepressants, 
fluoxetine and delineating the possible receptors 
involved which mediate its action. 
MATERIALS AND METHODS 
Ethical considerations 
The study began only after obtaining permission from 
the Institutional Animal Ethics Committee. 
Animals 
Thirty two healthy albino mice of either sex (16 males 
and 16 females) weighing between 25-30 grams, with 
normal behavior and activity were obtained from 
Haffkine Institute, Parel, Mumbai. Pregnant animals and 
those that had delivered once or used previously for any 
other experimental purpose were excluded from the 
study. The animals were housed in mice cages in the 
central animal house of the institution with free access to 
food and drinking water as per the Committee for the 
Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA) guidelines, for a period of 1 month 
prior to the study, so that they were acclimatized to the 
environment.  A 12-hour light and dark cycle was 
maintained. 
Study drugs 
Fluoxetine was obtained from Cadila Pharmaceuticals 
Limited. Naloxone was obtained from Samarth Pharma 
Limited. Ondansetron was obtained from Intas 
Pharmaceuticals Limited. Stock solutions of all the 
drugs were freshly prepared on the day of the 
experiment in normal saline (NS; 0.9% NaCl). In 
previous studies conducted, the effective dose of 
fluoxetine that did not induce sedation was found to be 5 
mg/kg. 
11
 This dose of fluoxetine was therefore used in 
our study.  Dose of naloxone and ondansetron were 
calculated based on previous studies.  
Experimental study groups and drug administration 
The 32 mice were divided into 4 groups of 8 mice (4 
male and 4 female mice) each. Group I received normal 
saline alone, group II received fluoxetine alone; group 
III received fluoxetine + naloxone; group IV received 
fluoxetine + ondansetron. Fluoxetine and naloxone were 
given subcutaneously whereas ondansetron was given 
intraperitoneally. The treatment groups are summarized 
in the Table. (see Table 1) 
 
Table 1: Treatment groups 
Groups Drug 1 Drug 2 
Group 1 (control) Normal saline - 
Group II Fluoxetine 5 mg/kg - 
Group III Fluoxetine 5 mg/kg Naloxone 2 mg/kg 
Group IV Fluoxetine 5 mg/kg Ondansetron 0.1 mg/kg 
 
Drugs were administered using 26 G tuberculin syringe 
using aseptic precautions. Normal saline, fluoxetine, and 
naloxone were administered subcutaneously (s.c.) in the 
nape of the neck. Naloxone was administered 10 
minutes prior to the administration of fluoxetine in 
group III. Ondansetron was administered 
intraperitoneally (i.p.).  
Evaluation of anti-nociceptive effect using Eddy’s hot 
plate 
The hot plate test was based on that described by Singh 
et al. and Eddy and Leimbach. 
12,13
 
A transparent glass cylinder (16-cm-high, 16-cm 
diameter) was used to keep the mice on the heated 
surface of the plate. The temperature of the hot plate 
was set to 55 + 0.5°C by using a thermoregulated pump. 
The animals were placed on the hot plate and the time 
until either licking or jumping occurred was recorded by 
stopwatch. The time of latency was defined as the time 
period between the zero point when the animal was 
placed on the hot plate surface and the time when the 
animal licked its forepaw or jumped off to avoid thermal 
pain. The animals which showed licking of paw or 
jumping from the hot plate after 10 seconds were 
removed from the study. 
Post treatment latencies were determined after 30 
minutes of administration of study drugs. To minimize 
tissue damage, a cut-off time (removing from the plate) 
of 30 seconds was adopted. The latencies of both 
forepaws’ licking and jumping were measured for each 
animal at 0, 15, 30, 60, and 120 minutes.  The accepted 
“zero time” of this study was 30 min after the 
administration of study drugs. 
Statistical analysis  
The data were expressed as the mean + S.D. Unpaired 
student’s “t” test was used to compare groups with each 
other. Probability (P) value of < 0.05 was taken as level 
of statistical significance. 
RESULTS 
The results of the study are described in this section. 
(See Table 2 and Figure 1) 
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Table 2: Comparison between different groups for latency to animal licking its forepaw or jumping off to 
avoid thermal pain on Eddy’s hot plate 
Post drug time interval 0 min 15 min 30 min 60 min 120 min 
Control 5.25 ± 0.46 5.88 ± 1.13 6.00 ± 1.07 5.63 ± 0.52 6.63 ± 1.30 
Fluoxetine 6.38 ± 1.06
*
 12.88 ± 2.90
**, α
 17.25 ± 1.75
**, 
α, β
 
20.13 ± 
4.32
**, α, ββ
 
7.88 ± 1.36 
β, 
δ¸ γ
 
Fluoxetine + Naloxone 7.50 ± 2.00 6.88 ± 0.99
$
 6.00 ± 1.07
$
 6.63 ± 1.19
$
 6.88 ± 0.99 
Fluoxetine + Ondansetron 5.75 ± 0.71
#
 6.38 ± 1.41
$
 7.00 ± 1.07
$
 6.13 ± 0.99
$
 6.63 ± 1.30 
n=8 mice in all groups 
*p<0.01, **p<0.001 versus control; $ p<0.001 versus fluoxetine; #p<0.05 versus fluoxetine + naloxone, using one-way ANOVA 
followed by post-hoc Tukey’s test. 
α p<0.001 versus 0 minutes; β p<0.01, ββ p<0.001 versus 15 minutes; δ p<0.001versus 30 minutes¸ γ p<0.001 versus 60 minutes, 
using repeated measures ANOVA followed by post-hoc Tukey’s test. 
 
 
Values represent mean and error bars represent the standard deviation. 
The accepted “0 min” of this study means 30 min after the administration of study drug. 
Figure 1. Comparison between different groups for latency to animal licking its forepaw or jumping off to 
avoid thermal pain on Eddy’s hot plate 
 
Fluoxetine produced a significant increase in the latency 
of licking of paw or jumping as compared to control at 
all time intervals except at 120 minutes with onset of 
antinociceptive effect within 30 min i.e. 0 min time 
interval  (p<0.01) and maximum effect at 60 min time 
interval  i.e. after  90 min of administration of fluoxetine 
(p<0.001). 
There was no significant difference between the control 
group and the fluoxetine + naloxone or fluoxetine + 
ondansetron combination group at any time point. Thus, 
it appears that pre-treatment with naloxone and 
ondansetron antagonized the antinociceptive effects of 
fluoxetine as the values are comparable to the control 
group. 
Pretreatment with naloxone and ondansetron in 
fluoxetine treated mice group significantly reduced the 
analgesic effect of fluoxetine at all time intervals 
(p<0.001 for fluoxetine + naloxone and fluoxetine + 
ondasetron versus fluoxetine alone at 15 min, 30 min, 
and 60 min). Thus it reflects that the antinociceptive 
effect of fluoxetine is antagonized by naloxone as well 
as ondansetron.  
There was no significant difference found when the 
combination group of fluoxetine + naloxone was 
compared with the combination group of fluoxetine + 
ondansetron at any time point. 
DISCUSSION 
In daily life the pain sensation is specifically evoked by 
potential or actual noxious (i.e. tissue damaging) stimuli 
applied to the body such as heat, squeezing a skin fold or 
over-rotating a joint.  The predictable correlation 
between the noxious stimulus and the pain sensation 
forces us towards avoiding behavior and situations that 
evoke pain. Pain during disease is different from 
“normal” pain. It occurs in the absence of external 
noxious stimuli, during mild stimulation or in an 
unpredictable way. 
[14]
 Pain is a symptom of many 
diseases requiring treatment with analgesics.  Severe 
pain due to chronic conditions needs the use of strong 
analgesics such as opioid drugs.  The addiction liability 
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of opioids has led to intensive search for compounds 
without this hazard. 
15
 Tricyclic antidepressants, even 
though their mechanism of action is not clear, have been 
used for decades for the treatment of chronic pain in 
patients without depression. Because of numerous 
undesirable side effects of traditional tricyclics, SSRIs 
with favorable side effects profile are preferred. 
10
 
Antidepressants are reported to be more effective than 
opioid analgesics in treating neuropathic or 
differentiation pain. Inhibition of the reuptake of 
monoamines is considered to be a major effect of 
antidepressants. 
11
 The analgesic effect of SSRIs has 
been shown both in animal models 
16,17,18
 and human 
cases suffering from chronic 
19,20 
but not in acute pain.  
However there appears to be some disparities in the 
results of these studies. Some studies indicated the 
presence of analgesic effects to SSRIs whereas others 
negated this observation.  Hence the present study was 
undertaken to evaluate the antinociceptive activity of 
fluoxetine, a long acting SSRI, and to find out its site of 
action.  
Central analgesic activity of fluoxetine was tested 
through an acute pain model of hot plate analgesiometer. 
In previous studies, the analgesic effects of fluoxetine 
was evaluated at a dose of 5 mg/kg 
11,20
 and the same 
dose was used for the current study. The doses of 
naloxone and ondansetron were also selected based on 
the previous studies. 
10,11, 15
 
The antinociceptive effects of fluoxetine and its 
interaction with naloxone and ondansetron were 
observed 30 minutes after the administration of 
fluoxetine i.e. at 0,15,30,60 and 120 min intervals, based 
on the previously published reports. 
10,11, 20
 
The number of mice to be used for this experiment was 
decided after reviewing the CPCSEA guidelines and 
previous study references to have minimum number of 
animals for particular animal experiment to get 
statistically significant data. 
21
 
It was observed that fluoxetine possesses significant 
antinociceptive effect with onset of action within 30 
minutes and maximal effect at 90 minutes post-
administration of the drug. These findings are in 
conjunction with the findings of Kurlekar et al. and 
Sikka et al. which showed dose dependent 
antinociceptive activity of fluoxetine.
11,20
 The 
combination groups of fluoxetine + naloxone and 
fluoxetine + ondansetron were comparable to the control 
group. This indicated that the antinociceptive effect of 
fluoxetine was blocked by naloxone and ondansetron. 
This suggests the contribution of opiodergic and 
serotonergic mechanisms in mediating antinociceptive 
action of fluoxetine. Even though there are no earlier 
studies on fluoxetine and ondansetron combination,  a 
study conducted by Duman et al. on paroxetine, another 
SSRI found  that  ondansetron significantly inhibited the 
antinociceptive effect of paroxetine which is similar  to 
the findings of the current study. 
10
 Opioid or Opioid-
like activity of fluoxetine and some SSRIs has been 
reported in few binding assays. Other studies have 
disputed the affinity of fluoxetine for opioid receptors. 
11
 
However in the present study the involvement of opioid 
receptor in the analgesic activity of fluoxetine was 
observed. 
Rafiran-Kopaei and Swell and Singh et al. also reported 
that Fluoxetine-induced 
antinociception was blocked by naloxone. 
22,17
 Gray AM 
also showed that antidepressants produce 
antinociception that can be blocked by opioid antagonist 
thus suggesting direct agonist-like actions of the 
antidepressants at opioid receptors. 
23
 Thus it is likely 
that fluoxetine acts through opioid pathways involving 
the µ opioid receptor.  
Also in the present study ondansetron, a 5HT3 receptor 
antagonist significantly inhibited the antinociceptive 
effect of fluoxetine.  This suggests the contribution of 5-
HT3 receptors in the antinociceptive action of 
fluoxetine. Certain published reports have also stated 
that both α-adrenoceptor and 5-HT receptor antagonists 
inhibit the antinociception mediated by antidepressants 
in various studies. Similarly, depletion of central NA 
systems with α-methyl-p-tyrosine and 5-HT systems 
with p-chlorophenylalanine inhibits antinociception by 
antidepressants. Within the spinal cord, activation of 
both NA and 5-HT receptors produces analgesia and NA 
and 5-HT mechanisms interact significantly. 
24
 
In another study by Abdalla S et al. it has been observed 
that fluoxetine blocks selectively the uptake of 5-HT, 
while mirtazapine is believed to increase both 
noradrenergic and serotonergic neurotransmission via 
blockade of central alpha-2 adrenergic auto and 
heteroreceptors increasing the availability of both 
amines at the synapse. Noradrenergic and serotonergic 
descending inhibitory and excitatory pathways are 
believed to play an important role in endogenous 
analgesic systems. Both noradrenaline and serotonin 
produce membrane hyperpolarization while decreasing 
the excitatory transmitter release from primary Aδ and C 
afferent fibers presynaptically and increasing the 
inhibitory transmitter release, including both GABA and 
Glycine, from the interneurons. 
2
 This further 
emphasizes the role of 5HT3 in analgesic activity of 
fluoxetine.  Studies by Duman EN et al. and Patil R et al. 
also support these findings. 
10, 15
 
In the present study when we compared the combination 
of fluoxetine + naloxone with the combination of 
fluoxetine + ondansetron, difference was not significant. 
Thus it shows that analgesic activity of fluoxetine was 
blocked by both naloxone and ondansetron, hence 
indicating the involvement of opiodergic and 
serotonergic mechanisms. According to explanation 
provided in the previously published studies it was 
thought that 5HT descending system plays an important 
role in morphine analgesia which mediates through µ 
opioid receptor. The analgesic action of systemic opioids 
can be blocked by depletion of 5HT by inhibiting its 
synthesis. In the present study we have also found that 
analgesic activity of fluoxetine is mediated through µ 
opioid receptor and 5HT3 receptors. 
17
 
Thus there can be an interplay between both the 
receptors i.e. µ opioid receptor and 5HT3 receptors in 
mediating the antinociceptive activity of fluoxetine so 
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even blockade one receptor  can significantly inhibit the 
antinociceptive activity of fluoxetine. 
So from the present study it is confirmed that fluoxetine 
has antinociception potential that is antagonized by 
naloxone and ondansetron. This combined finding 
suggests an involvement of opiodergic system by 
increasing the release of endogenous opioid peptides or 
opioid receptors activation and serotonergic mechanisms 
through serotonergic receptors activation induced by 
fluoxetine. 
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